220 related articles for article (PubMed ID: 35499757)
1. MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.
Hemming ML; Benson MR; Loycano MA; Anderson JA; Andersen JL; Taddei ML; Krivtsov AV; Aubrey BJ; Cutler JA; Hatton C; Sicinska E; Armstrong SA
Cancer Discov; 2022 Jul; 12(7):1804-1823. PubMed ID: 35499757
[TBL] [Abstract][Full Text] [Related]
2. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
3. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL.
Fassunke J; Blum MC; Schildhaus HU; Zapatka M; Brors B; Künstlinger H; Büttner R; Wardelmann E; Merkelbach-Bruse S
BMC Mol Biol; 2010 Dec; 11():100. PubMed ID: 21171987
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.
Hemming ML; Lawlor MA; Zeid R; Lesluyes T; Fletcher JA; Raut CP; Sicinska ET; Chibon F; Armstrong SA; Demetri GD; Bradner JE
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5746-E5755. PubMed ID: 29866822
[TBL] [Abstract][Full Text] [Related]
5. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
6. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
7. KIT gene mutations in gastrointestinal stromal tumor.
Kang W; Zhu C; Yu J; Ye X; Ma Z
Front Biosci (Landmark Ed); 2015 Jun; 20(6):919-26. PubMed ID: 25961532
[TBL] [Abstract][Full Text] [Related]
8. Translational insights into gastrointestinal stromal tumor and current clinical advances.
Hemming ML; Heinrich MC; Bauer S; George S
Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
10. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Falkenhorst J; Grunewald S; Mühlenberg T; Marino-Enriquez A; Reis AC; Corless C; Heinrich M; Treckmann J; Podleska LE; Schuler M; Fletcher JA; Bauer S
Oncotarget; 2016 Jul; 7(27):41390-41403. PubMed ID: 27167336
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
13. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
14. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
15. New insights into the clinical management of advanced gastrointestinal stromal tumors.
Italiano A
Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
[TBL] [Abstract][Full Text] [Related]
16. [Application and value of mutation detection in diagnosis and treatment of gastrointestinal stromal tumor].
Cao H; Wang M
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):208-11. PubMed ID: 23536336
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
18. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
19. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
Schaefer IM; DeMatteo RP; Serrano C
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913
[TBL] [Abstract][Full Text] [Related]
20. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
